-
Product Insights
Corneal Graft Rejection Disease - Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Corneal Graft Rejection Global Clinical Trials Review, H1, 2019" provides an overview of Corneal Graft Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Corneal Graft Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Myasthenia Gravis - Epidemiology Forecast to 2028
Myasthenia gravis (MG) is the most common neuromuscular junction disorder, and is characterized by a fluctuating degree and variable combination of weakness in ocular, bulbar, limb, and respiratory muscles (Lai and Tseng, 2010). In this disease, receptors for acetylcholine at the neuromuscular junction are blocked, altered, or destroyed by the antibodies (immune proteins), which prevent the muscle from contracting. In some cases, antibodies to other proteins, such as the muscle-specific receptor tyrosine kinase (MuSK) protein, can also lead to impaired...
-
Sector Analysis
Axial Spondyloarthritis - Epidemiology Forecast to 2028
Axial spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Based on sacroiliac changes on conventional radiographs, AxSpA is classified into radiographic (r-AxSpA) or nonradiographic (nr-AxSpA) depending on the presence or absence of radiographic changes at the sacroiliac joints. Patients traditionally classified as ankylosing spondylitis (AS) would be considered as r-AxSpA. Some of nr-AxSpA progress to AS and some do not (Sieper...
-
Sector Analysis
Axial Spondyloarthritis - Epidemiology Forecast in Asia-Pacific Markets to 2028
Axial spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Based on sacroiliac changes on conventional radiographs, AxSpA is classified into radiographic (r-AxSpA) or nonradiographic (nr-AxSpA) depending on the presence or absence of radiographic changes at the sacroiliac joints. Patients traditionally classified as ankylosing spondylitis (AS) would be considered as r-AxSpA. Some of nr-AxSpA progress to AS and some do not (Sieper...
-
Sector Analysis
Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030
Systemic sclerosis (SSc) is an autoimmune disorder of small arteries, microvessels, and connective tissue. SSc is characterized by the buildup of scar tissue (fibrosis) and vascular obliteration in the skin and organs, particularly the lungs, heart, and digestive tract (Orphanet, 2010). The signs and symptoms of SSc usually begin with episodes of Raynaud's phenomenon (RP). The other signs usually appear a few months later in the dcSSc subset and some years later in the lcSSc subset. In lcSSc, skin involvement...
-
Product Insights
Myasthenia Gravis - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Myasthenia Gravis - Global Clinical Trials Review, H2, 2021" provides an overview of Myasthenia Gravis Clinical trials scenario. This report provides top line data relating to the clinical trials on Myasthenia Gravis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides...
-
Product Insights
Peanut Allergy - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Peanut Allergy - Global Clinical Trials Review, H2, 2021" provides an overview of Peanut Allergy Clinical trials scenario. This report provides top line data relating to the clinical trials on Peanut Allergy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides...
-
Product Insights
Juvenile Rheumatoid Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Juvenile Rheumatoid Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Juvenile Rheumatoid Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Rheumatoid Arthritis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news...
-
Product Insights
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics,...
-
Product Insights
Wiskott-Aldrich Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Wiskott-Aldrich Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Wiskott-Aldrich Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Wiskott-Aldrich Syndrome, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.